{"id":"W3168005110","doi":"10.1055/s-0041-1730167","title":"IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)","year":2021,"lang":"en","type":"article","venue":"Senologie - Zeitschrift für Mammadiagnostik und -therapie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Atezolizumab; Placebo; Oncology; Medicine; Paclitaxel; Breast cancer; Internal medicine; Doxorubicin; Cyclophosphamide; Quality of life (healthcare); Stage (stratigraphy); Triple-negative breast cancer; Chemotherapy; Cancer; Pembrolizumab; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003502645,0.001249187,0.001698653,0.0004280109,0.000322375,0.0008639934,0.001270617,0.001728247,0.006607457],"category_scores_gemma":[0.001999807,0.000376917,0.003278675,0.0006373525,0.001151708,0.0008298762,0.0007493889,0.002711543,0.0007651009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006637385,"about_ca_system_score_gemma":0.001121695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004998682,"about_ca_topic_score_gemma":0.001034913,"domain_scores_codex":[0.9984465,0.0009566934,0.000106646,0.0002010773,0.0001197704,0.0001694018],"domain_scores_gemma":[0.9977446,0.0007245473,0.0006531244,0.0001693909,0.00012789,0.0005805121],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9224701,0.01522606,0.007274994,0.001383402,0.00274014,0.0001105125,0.00008627187,0.0005574768,0.01021014,0.0001073617,0.001151982,0.03868165],"study_design_scores_gemma":[0.622366,0.3404404,0.02737884,0.0001338641,0.003581991,0.0002616304,0.00004493527,0.0003831297,0.003148243,0.0002029972,0.002017203,0.00004092652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977273,0.01118805,0.0006725957,0.001011836,0.0001332966,0.002606752,0.004231683,0.00008737706,0.002795283],"genre_scores_gemma":[0.9866333,0.002755344,0.001311128,0.001206939,0.0003656053,0.002363567,0.004002825,0.00003036247,0.001330943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006607457,"threshold_uncertainty_score":0.02210408,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0626525346854209,"score_gpt":0.3918539450723508,"score_spread":0.32920141038693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}